Precision BioSciences Stock Faces Technical Pressure Despite Long-Term Prospects

Precision BioSciences Inc. shares extended their recent decline, closing the latest trading session with significant losses. The clinical-stage biotechnology company’s equity displayed notable technical weakness throughout Friday’s session.

Trading Activity and Price Movement

The stock concluded trading at $4.90, marking a daily decline of 2.39%. Throughout the session, shares traded within a range spanning from $4.84 to $5.08, representing an intraday swing of nearly 5%.

Trading volume presented a notable contrast, dropping by approximately 83,000 shares to reach just 41,907 units exchanged. Since triggering a breakout signal the previous Monday, the stock has surrendered 4.5% of its value.

Technical Analysis Presents Divergent Signals

Chart analysis reveals conflicting indicators for Precision BioSciences. The short-term moving average currently flashes a sell signal, establishing resistance at $4.97. Conversely, the longer-term average suggests a buy opportunity, providing support at the $4.78 level.

Key technical levels include:
* Last close: $4.90
* Daily change: -2.39%
* 52-week range: $3.61 – $11.09
* Resistance (short-term): $4.97
* Support (long-term): $4.78

Should investors sell immediately? Or is it worth buying Precision BioSciences Inc?

Despite receiving a buy signal from the 3-month MACD indicator, the stock recently faced a downgrade from “Buy” to “Sell” based on what analysts termed “minor technical weaknesses.”

Quarterly Results Disappoint Investors

The company’s Q2 2025 financial results, released August 7, fell substantially short of expectations. Precision BioSciences reported revenue of just $20,000 compared to projections of $6.27 million. More significantly, the company posted a loss per share of ($2.13), dramatically wider than the anticipated ($0.09) loss.

Pipeline Developments Offer Future Potential

Amid the disappointing financial performance, several clinical programs show promise. The Phase 1 study for PBGENE-HBV continues to advance, with one patient demonstrating a sustained 50% reduction in hepatitis B surface antigen. Clinical data for PBGENE-DMD is anticipated in 2026.

The company maintains a cash position of $84.8 million, which management believes provides sufficient funding through the second half of 2027. This financial runway may provide the necessary resources to achieve critical development milestones despite recent setbacks.